Clarithromycin tablets, this product is suitable for the following infections caused by clarithromycin sensitive bacteria: 1. Nasopharynx infection: tonsillitis, pharyngitis, paranasal sinusitis; 2. Lower respiratory tract infection: including bronchitis, bacterial pneumonia, atypical pneumonia; 3. Skin infection, pustulosis, erysipelas, folliculitis, furuncle and wound infection.
  1. Pharmacology This product is a macrolide antibiotic. It has inhibitory effect on Gram positive bacteria such as Staphylococcus aureus, Streptococcus, pneumococcus, etc. it also has inhibitory effect on some gram negative bacteria such as Haemophilus influenzae, pertussis, Neisseria gonorrhoeae, Legionella pneumophila and some anaerobic bacteria such as Bacteroides fragilis, Streptococcus digestion, Propionibacterium acnes, etc. in addition, it also has inhibitory effect on mycoplasma inhibition. The antibacterial activity of this product is similar to erythromycin in vitro, but its antibacterial activity against some bacteria such as Staphylococcus aureus, Streptococcus and Haemophilus influenzae is stronger than erythromycin in vivo. There was cross resistance between this product and erythromycin. The mechanism of action of this product is to inhibit the binding of nuclear protein 50S subunit and inhibit protein synthesis.
  2. Toxicology except that chromosome aberration test in vitro was weakly positive for one time and negative for the other, other in vitro mutagenic tests such as Salmonella / mammalian cell microsome test, bacterial mutation frequency test, rat hepatocyte DNA synthesis test, mouse lymphoma test, mouse dominant lethal test and mouse micronucleus test were all negative. Studies on reproduction and reproduction showed that 160 mg / kg clarithromycin (160 mg / kg in body surface area) had no effect on estrus, fertility, number and survival rate of offspring. When monkeys were given clarithromycin 150mg / kg (body surface area, 2.4 times of the maximum recommended dose for human use), embryos were lost. Long term toxicity studies have not confirmed the carcinogenicity of clarithromycin.